Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 852 participants.

Also called NCT07609654

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 852 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07609654
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07609654. Randomized; single masking; primary purpose treatment. Start 2026-10-26 (anticipated); primary completion 2031-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic Stroke
Acronym
OASIS-AF
Condition
Intracerebral Hemorrhage
Condition
Atrial Fibrillation (AF)
Condition
Ischemia Stroke
Intervention (Drug)
Apixaban
Intervention (Other)
No Oral Anticoagulation Strategy
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct07609654
Content hash
45bac8d245f138d5a7bd439613264fe8942f51087df73278e408709ded9db28b